Northern Trust Corporation Form 8.3 - Allergan (3214M)
September 13 2019 - 7:54AM
UK Regulatory
TIDMTTM TIDM0Y7T
RNS Number : 3214M
Northern Trust Corporation
13 September 2019
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing Northern Trust Corporation
(Note 1)
Company dealt in Allergan PLC
===========================
Class of relevant security Common Stock USD 0.0033
to which the dealings
being disclosed relate
(Note 2)
===========================
Date of dealing 12(th) September 2019
===========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
========== ====== =========== ======
(1) Relevant securities 3,703,490 1.13%
================== ===================
(2) Derivatives (other
than options)
================== ===================
(3) Options and agreements
to purchase/sell
================== ===================
Total 3,703,490 1.13%
================== ===================
* Note: The difference in holdings from yesterday and today not
explained by transactions, can be explained by stock transfers of
205 securities into the relevant accounts.
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit ($)
securities
BUY 170 166.39
=========================== ========================
BUY 30 166.35
=========================== ========================
BUY 29 166.68
=========================== ========================
SELL 9 166.35
=========================== ========================
BUY 15 166.35
=========================== ========================
BUY 519 166.94
=========================== ========================
BUY 10 166.35
=========================== ========================
BUY 5 166.35
=========================== ========================
BUY 249 166.68
=========================== ========================
BUY 1 166.35
=========================== ========================
BUY 48 166.35
=========================== ========================
BUY 2 166.68
=========================== ========================
BUY 6 166.35
=========================== ========================
BUY 3 166.35
=========================== ========================
BUY 4 166.48
=========================== ========================
SELL 7 166.35
=========================== ========================
SELL 11 166.35
=========================== ========================
SELL 35 166.35
=========================== ========================
SELL 3 166.62
=========================== ========================
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 13(th) September 2019
Contact name Trish Mc Menamin
======================
Telephone number 3535717287
======================
If a connected EFM, name
of offeree/offeror with
which connected
======================
If a connected EFM, state
nature of connection (Note
10)
======================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEEAANDFSFNEFF
(END) Dow Jones Newswires
September 13, 2019 08:54 ET (12:54 GMT)
Allergan (LSE:0Y7T)
Historical Stock Chart
From Apr 2024 to May 2024
Allergan (LSE:0Y7T)
Historical Stock Chart
From May 2023 to May 2024
